GlassScriptPhysician profile
Alysa Sonnentag
NPI 1003537325
$2,718.22
in general payments reported to CMS, 2019-2025
30 companies · $701 in 2025
The $701 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $49.26 · 2023: $899 · 2024: $1,070 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $424.22 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $267.33 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $248.76 | 2023-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $128.13 | 2023-2025 | Trintellix |
| Amgen INC. | $124.93 | 2023-2025 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $117.45 | 2023-2024 | Myfembree, Gemtesa |
| Aimmune Therapeutics, INC. | $86.55 | 2024-2025 | Zenpep, Vowst |
| Novo Nordisk INC | $80.38 | 2023-2025 | Wegovy, Ozempic |
| Pfizer INC. | $79.43 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $79.03 | 2023-2025 | Eliquis |
| Exact Sciences Corporation | $72.69 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $55.97 | 2024 | |
| Lilly USA, LLC | $54.32 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.41 | 2023-2024 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.31 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.35 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $37.26 | 2023 | Verquvo, Dificid, Steglujan |
| Lundbeck LLC | $29.32 | 2025 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $28.58 | 2025 | Neffy |
| Sunovion Pharmaceuticals INC. | $27.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.40 | 2024 | Evkeeza |
| Axsome Therapeutics, INC. | $24.73 | 2024 | Auvelity |
| Acadia Pharmaceuticals INC | $23.70 | 2024 | Daybue |
| Daiichi Sankyo INC. | $21.54 | 2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $20.96 | 2025 | Rexulti |
| Mylan Specialty L.P. | $20.00 | 2023 | Yupelri |
| Corium, LLC | $17.06 | 2023 | Azstarys |
| Ibsa Pharma INC. | $16.51 | 2023 | Tirosint, Licart |
| Echosens North America, INC. | $15.66 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alysa Sonnentag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.